Doximity closed fiscal 2026 Q4 with revenue above the high end of its guidance range, driven by subscription service growth, and generated record free cash flow. This performance strengthened liquidity and exceeded analysts’ consensus estimates.

Management designated the coming 12 months as an “AI investment year,” planning to ramp R&D and product development spending on machine learning tools, expert networks and clinical workflow enhancements to drive long-term growth.

Despite the overall revenue beat, management noted that near-term growth in the digital pharma advertising market is subdued, reflecting cautious client budgets and slower campaign rollouts.